# (19) World Intellectual Property Organization International Bureau



## 

(43) International Publication Date 18 September 2003 (18.09.2003)

**PCT** 

# (10) International Publication Number WO 2003/076472 A3

- (51) International Patent Classification<sup>7</sup>: C07K 16/30, C12N 5/28, 15/08, G01N 33/574, 33/577, A61K 51/10, 39/395, 47/48, A61P 35/00
- (21) International Application Number:

PCT/IB2003/001335

- (22) International Filing Date: 10 March 2003 (10.03.2003)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

102 10 427.1

9 March 2002 (09.03.2002) DE

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:

US

102 10 427.1 (CIP)

Filed on

8 March 2002 (08.03.2002)

- (71) Applicant (for all designated States except US): ONCOMAB GMBH [DE/DE]; c/o IGZ BioMed, Friedrich-Bergius-Ring 15, 97076 Würzburg (DE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): VOLLMERS, Heinz, Peter [DE/DE]; Budapeststrasse 23, 97084 Würzburg (DE). MUELLER-HERMELINK, Hans, Konrad [DE/DE]; Heinrich-Zeuner-Strasse, 97082 Würzburg (DE).

- (74) Agents: WEICKMANN, F., A. et al.; Weickmann & Weickmann, Postfach 860 820, 81635 München (DE).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:

- with international search report
- with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description
- (88) Date of publication of the international search report:

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

2003/076472 AC

International, ition No PCT/IB 03/01335

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 CO7K16/30 C12N5/28 G01N33/574 G01N33/577 C12N15/08 A61K51/10 A61K39/395 A61K47/48 A61P35/00 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 CO7K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) BIOSIS, EPO-Internal, SEQUENCE SEARCH, WPI Data, PAJ, MEDLINE, EMBASE C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Relevant to daim No. 1-6, 13,WO 01 83560 A (ICHIKAWA KIMIHISA ; KIMBERLY ROBERT P (US); KOOPMAN WILLIAM J (US);) 14, 17-20, 8 November 2001 (2001-11-08) 26-53 abstract page 1, line 25 - line 31 page 3, line 7 - line 9 page 4, line 25 - line 28 page 5, line 20 - line 30 page 5, line 22 - line 25 page 6, line 3 - line 5 page 6, line 25 - line 27 page 12, line 18 - line 31 page 20, line 1 - line 8 page 29, line 27 - line 28 page 30, line 17 - line 29 page 35, line 6 - line 11 page 36, line 15 - line 17 page 58, line 1 - line 2 -/--Patent family members are listed in annex. Further documents are listed in the continuation of box C. Special categories of cited documents: "I" later document published after the international filing date or priority date and not in conflict with the application but "A" document defining the general state of the art which is not cited to understand the principle or theory underlying the considered to be of particular relevance invention \*E\* earlier document but published on or after the International "X" document of particular relevance; the claimed invention filing date cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another \*Y\* document of particular relevance; the claimed invention citation or other special reason (as specified) cannot be considered to involve an inventive step when the "O" document referring to an oral disclosure, use, exhibition or document is combined with one or more other such documents, such combination being obvious to a person skilled other means in the art. \*P\* document published prior to the international filing date but '&' document member of the same patent family later than the priority date claimed Date of mailing of the international search report Date of the actual completion of the international search 28/11/2003 3 November 2003 Authorized officer Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Irion, A Fax: (+31-70) 340-3016

Internations stion No PCT/IB 03/01335

		PCI/18 U3/U1335
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category •	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 13844 A (CAMBRIDGE ANTIBODY TECH; TEMPEST PHILIP RONALD (GB); THOMSON JULIA) 17 April 1997 (1997-04-17) figures 1,2,19 page 17, line 25 -page 18, line 21 page 1, line 8 - line 11 page 38, line 6 - line 9 page 38, line 16 - line 20 claims 1-34	9,12-16, 21,22, 26,52,53
X	WO 01 62932 A (AMGEN INC) 30 August 2001 (2001-08-30) claim 9	23,26
X	EP 1 106 183 A (GENENTECH INC ;REGENTS BOARD OF (US)) 13 June 2001 (2001-06-13)	3,6, 12-14, 16, 29-33, 36-41, 44-49, 52,53
	page 9, line 23 - line 30 page 17, line 15 - line 24 page 24, line 46 - line 55 page 5, line 5 - line 7 page 10, line 38 - line 44 page 14, line 26 - line 34	
X	BRAENDLEIN STEPHANIE ET AL: "Characterization of five new fully human monoclonal IgM antibodies isolated from carcinoma patients" PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 43, March 2002 (2002-03), page 970 XP001155782 93rd Annual Meeting of the American Association for Cancer Research; San Francisco, California, USA; April 06-10, 2002, March, 2002 ISSN: 0197-016X the whole document	1-53
X	BRAENDLEIN STEPHANIE ET AL: "Human monoclonal IgM antibodies with apoptotic activity isolated from cancer patients." HUMAN ANTIBODIES, vol. 11, no. 4, 2002, pages 107-119, XP009020163 ISSN: 1093-2607 the whole document	1-53

Internation stion No PCT/IB 03/01335

		PC1/1B 03/01335		
C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT			
Category *	Citation of document, with indication, where appropriate, of the relevant passages		Relevant to claim No.	
A	MENG RAYMOND D ET AL: "p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma" EXPERIMENTAL CELL RESEARCH, vol. 262, no. 2, 15 January 2001 (2001-01-15), pages 154-169, XP002260126 ISSN: 0014-4827 the whole document		1-53	
A	HUANG YING ET AL: "Sulindac sulfide-induced apoptosis involves death receptor 5 and the caspase 8-dependent pathway in human colon and prostate cancer cells"  CANCER RESEARCH, vol. 61, no. 18, 15 September 2001 (2001-09-15), pages 6918-6924, XP002260127 ISSN: 0008-5472 the whole document		1-53	
		-		
		•		

International application No. PCT/IB 03/01335

'Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This Inte	ernational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. 🗶	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
	Although claims 36-51 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of Invention is lacking (Continuation of Item 2 of first sheet)
This Inte	ernational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this international Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the Invention first mentioned in the claims; it is covered by claims Nos.:
Remark	The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT Information on patent family members

Internationa .. ation No PCT/IB 03/01335

Patent document		Publication		Patent family		Publication
cited in search report		date		member(s)		date
WO 0183560	A	08-11-2001	AU	5936601	A	12-11-2001
,			CA	2407965	A1	08-11-2001
			CN	1440424	•	03-09-2003
			CZ		A3	14-05-2003
			EP	1287035	- • •	05-03-2003
,			NO	20025253		18-12-2002
			WO	0183560	•	08-11-2001
		.,,	WU 	0163300		00-11-2001
WO 9713844	Α	17-04-1997	AT	190650	T	15-04-2000
			AT	199091	T	15-02-2001
•			AU	702049	B2	11-02-1999
		· .	AU	7140596	A	30-04-1997
		·	CA	2233042		17-04-1997
			DE		D1	20-04-2000
			DE	69607191		28-09-2000
•			DE	69611766	_	15-03-2001
			DE		T2	02-08-2001
				945464	. —	07-05-2001
•			DK EP	0853661	=	22-07-1998
				0945464		
			EP			29-09-1999
			ES	2146020		16-07-2000
			ES	2156035		01-06-2001
			WO	9713844		17-04-1997
			GB	2305921	-	23-04-1997
			GR	3033436		29-09-2000
			GR	3035775	•	31-07-2001
			JP	2000500643		25-01-2000
			PT	853661	T	31-08-2000
			PT	945464	T	31-07-2001
WO 0162932	A	30-08-2001	US	2003103978	Δ1	05-06-2003
WO 0102332	11	30 00 2001	AU	3868001		03-09-2001
			CA	2400929		30-08-2001
			EP	1257648		20-11-2002
•			JP	2003523772		12-08-2003
			WO	0162932		30-08-2001
	- 45 <del></del>		WU 	0102932		30-00-2001
EP 1106183	Α	13-06-2001	EP	1106183	A2	13-06-2001
			AU	4982097	Α	15-05-1998
			BR	9712410	Α	19-10-1999
			CN	1234072	A	03-11-1999
			EP	0931147		28-07-1999
•			JP	2001504326	: : <del>-</del>	03-04-2001
			JP	2001304520		31-10-2001
			KR	2000049261		25-07-2000
			TR	9901615		22-11-1999
			WO	9817797	<del>-</del>	30-04-1998
			ZA	9709185		14-04-1998
			<i>,</i> L	W / L W L A A	<b>A</b>	1 4 一 1 4 4 4